Skip to main content

Table 2 Secondary outcomes

From: Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease

  Once-daily Twice-daily P Value
mUPDRS 17.5 ± 8.2 17.1 ± 8.9 0.324
Hoehn and Yahr stage 2.1 ± 0.6 2.1 ± 0.6 0.260
Excessive daytime sleepiness 6.3 ± 5.2 6.4 ± 4.8 0.498
Compliance (%) 98.4 ± 3.9 97.6 ± 3.8 0.112
Sleep questionnaire
  Overall quality of sleep 2.9 ± 2.6 3.2 ± 2.5 0.307
  Nocturnal off-symptoms 2.9 ± 3.2 3.1 ± 3.2 0.396
  Early morning off symptoms 2.5 ± 3.3 2.9 ± 3.2 0.384
PGI-I, no (%)
  Overall 32 (52.5) 42 (68.9) 0.078
  Off duration 27 (44.3) 38 (62.3) 0.035a
  Worst wearing-off severity 28 (45.9) 34 (55.7) 0.238
  Dyskinesia duration 13 (21.3) 16 (26.2) 0.549
  Dyskinesia severity 16 (26.2) 15 (24.6) 1.000
  1. a P <0.005.
  2. mUPDRS, Unified Parkinson’s Disease Rating Scale part 3; PGI-I, patient global impressions of improvement.